| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 奥瑞德光电股份有限公司是西部地区最大的西药生产企业和西部地区唯一的麻醉药品定点生产基地.在生产工艺方面,公司拥有国内一流的麻醉药品、药品缓释、冻干粉生产技术以及国内一流的化学药品生产设备.因此,公司获得与葛兰素、罗氏、藤泽等多家国际制药巨头合作的机会.公司产品以普药为主,种类众多,常年生产的品种约200个,几乎涵盖普通诊所常用药物.公司获准成为首批生产注射用青霉素钠、注射用头孢唑啉钠对乙酰氨基酚片和颠茄片定点企业.公司的实际控制人为实力雄厚的太极集团有限公司,已直接或间接控股了太极集团、桐君阁、西南药业三家上市公司.太极集团的医药工业分销体系和桐君阁的医药商业分销体系将为西南药业发展规模经营提供强大的支持.随着医改推进,公司的规模优势、地域优势以及"纯普药"的品种优势都将逐渐体现。2015年5月公司发行股份购买资产，公司主营业务变更为蓝宝石晶体材料、单晶炉及蓝宝石制品的研发、生产和销售。 | ||||||||||||||||||||||||
| Main Business | 蓝宝石晶体生长专用设备、蓝宝石晶体材料、蓝宝石制品的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 江洋 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 梁影 | ||||||||||||||||||||||||
| Solicitors | 北京国枫律师事务所 | ||||||||||||||||||||||||
| Auditors | 天健会计师事务所（特殊普通合伙）;大华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0451-51076628 | ||||||||||||||||||||||||
| Fax No | 0451-51076628 | ||||||||||||||||||||||||
| Website | www.aurora-sapphire.cn | ||||||||||||||||||||||||
| zhengquan@aurora-sapphire.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 12/07/1993 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.244 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 0.384 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 3.460B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |